2.54
price up icon0.40%   0.01
after-market Handel nachbörslich: 2.55 0.010 +0.39%
loading
Schlusskurs vom Vortag:
$2.53
Offen:
$2.72
24-Stunden-Volumen:
22,180
Relative Volume:
0.53
Marktkapitalisierung:
$21.56M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.47M
KGV:
-0.2861
EPS:
-8.877
Netto-Cashflow:
$-10.85M
1W Leistung:
-11.19%
1M Leistung:
-6.96%
6M Leistung:
-32.80%
1J Leistung:
+504.76%
1-Tages-Spanne:
Value
$2.52
$2.74
1-Wochen-Bereich:
Value
$2.41
$2.9783
52-Wochen-Spanne:
Value
$0.38
$6.7499

Neurobo Pharmaceuticals Inc Stock (NRBO) Company Profile

Name
Firmenname
Neurobo Pharmaceuticals Inc
Name
Telefon
(857) 702-9600
Name
Adresse
545 CONCORD AVENUE, CAMBRIDGE, MA
Name
Mitarbeiter
8
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
NRBO's Discussions on Twitter

Neurobo Pharmaceuticals Inc Stock (NRBO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2020-06-15 Eingeleitet H.C. Wainwright Buy

Neurobo Pharmaceuticals Inc Aktie (NRBO) Neueste Nachrichten

pulisher
Oct 10, 2024

NRBO stock touches 52-week low at $2.55 amid market challenges - Investing.com

Oct 10, 2024
pulisher
Oct 07, 2024

NeuroBo Pharmaceuticals Unveils Updated Corporate Presentation - TipRanks

Oct 07, 2024
pulisher
Oct 01, 2024

NRBO stock touches 52-week low at $2.9 amid market challenges By Investing.com - Investing.com South Africa

Oct 01, 2024
pulisher
Oct 01, 2024

NRBO stock touches 52-week low at $2.9 amid market challenges - Investing.com India

Oct 01, 2024
pulisher
Oct 01, 2024

NRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25… - Zacks Small Cap Research

Oct 01, 2024
pulisher
Sep 30, 2024

NeuroBo reports positive early trial results for obesity drug By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 30, 2024

NeuroBo reports positive early trial results for obesity drug - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

We're A Little Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Rate - Yahoo Finance

Sep 30, 2024
pulisher
Sep 30, 2024

NeuroBo’s DA-1726 Shows Promise in Obesity Trial Phase 1 - TipRanks

Sep 30, 2024
pulisher
Sep 25, 2024

Affinity Asset Advisors LLC Invests $432,000 in NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) - Defense World

Sep 25, 2024
pulisher
Sep 24, 2024

Nutkao, transaction in closing with Morocco's sovereign wealth fundEFA News - EFA News - European Food Agency

Sep 24, 2024
pulisher
Sep 24, 2024

Berkley W R Corp Boosts Holdings in Nabors Energy Transition Corp. II (NASDAQ:NETD) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Bank of Montreal Can Decreases Stock Position in Novo Nordisk A/S (NYSE:NVO) - Defense World

Sep 24, 2024
pulisher
Sep 23, 2024

National Bank of Canada (OTCMKTS:NTIOF) Hits New 1-Year High at $94.20 - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

70,000 Shares in Neurogene Inc. (NASDAQ:NGNE) Purchased by Integral Health Asset Management LLC - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study - Yahoo Finance

Sep 23, 2024
pulisher
Sep 23, 2024

BMO maintains stock target on Novo Nordisk, cites trial results - Investing.com

Sep 23, 2024
pulisher
Sep 23, 2024

Lombard Odier Asset Management Europe Ltd Reduces Stock Position in nVent Electric plc (NYSE:NVT) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Avoro Capital Advisors LLC Makes New Investment in Neurogene Inc. (NASDAQ:NGNE) - Defense World

Sep 23, 2024
pulisher
Sep 21, 2024

National Bank of Canada (OTCMKTS:NTIOF) Increases Dividend to $0.81 Per Share - MarketBeat

Sep 21, 2024
pulisher
Sep 20, 2024

Amalgamated Bank Reduces Holdings in nVent Electric plc (NYSE:NVT) - Defense World

Sep 20, 2024
pulisher
Sep 20, 2024

Dong-A ST executives sell NeuroBo Pharmaceuticals shares worth over $1,500 - Investing.com

Sep 20, 2024
pulisher
Sep 20, 2024

BMO sustains stock target, outperform on Novo Nordisk amid trial results - Investing.com India

Sep 20, 2024
pulisher
Sep 20, 2024

Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results - Investopedia

Sep 20, 2024
pulisher
Sep 20, 2024

What's Going On With NovaBay Pharmaceuticals Shares Friday? - Benzinga

Sep 20, 2024
pulisher
Sep 20, 2024

Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients - Yahoo Finance

Sep 20, 2024
pulisher
Sep 20, 2024

Novo Nordisk Shares Slide After Disappointing Obesity Pill Trial - Finimize

Sep 20, 2024
pulisher
Sep 20, 2024

Novo Nordisk shares drop more than 4% on disappointing obesity pill data - The Economic Times

Sep 20, 2024
pulisher
Sep 20, 2024

NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear? - Yahoo Finance

Sep 20, 2024
pulisher
Sep 20, 2024

TD Cowen Reiterates Buy Rating on Novo Nordisk (NVO) Following Monlunabant Obesity Update - StreetInsider.com

Sep 20, 2024
pulisher
Sep 20, 2024

Novo Nordisk shares drop nearly 5% on disappointing obesity pill data - Yahoo Finance

Sep 20, 2024
pulisher
Sep 20, 2024

Novo Shares Fall on Safety Data for New Weight-Loss Drug - BNN Bloomberg

Sep 20, 2024
pulisher
Sep 20, 2024

Novo drops to 1-month low after Monlunabant trial data - XM

Sep 20, 2024
pulisher
Sep 20, 2024

NeuroBo shareholders approve significant stock issuance By Investing.com - Investing.com Australia

Sep 20, 2024
pulisher
Sep 20, 2024

NeuroBo shareholders approve significant stock issuance - Investing.com India

Sep 20, 2024
pulisher
Sep 19, 2024

Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential (NYSE:NVO) - Seeking Alpha

Sep 19, 2024
pulisher
Aug 21, 2024

NRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24… - Zacks Small Cap Research

Aug 21, 2024
pulisher
Aug 14, 2024

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update - citybiz

Aug 14, 2024
pulisher
Aug 14, 2024

NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow

Aug 14, 2024
pulisher
Aug 14, 2024

NeuroBo concludes subject enrolment in SAD portion of obesity treatment trial - Clinical Trials Arena

Aug 14, 2024
pulisher
Aug 13, 2024

NeuroBo Completes First Phase 1 Enrollment for Obesity Drug Trial - TipRanks

Aug 13, 2024
pulisher
Aug 06, 2024

NeuroBo partners for long-acting obesity treatment - Investing.com India

Aug 06, 2024
pulisher
Aug 06, 2024

NeuroBo Partners for Monthly Dual-Action Diabetes Drug Development - TipRanks

Aug 06, 2024
pulisher
Aug 06, 2024

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity - StockTitan

Aug 06, 2024
pulisher
Jul 30, 2024

NeuroBo licenses diabetic neuropathy drug to MThera Pharma By Investing.com - Investing.com Nigeria

Jul 30, 2024
pulisher
Jul 30, 2024

NeuroBo licenses diabetic neuropathy drug to MThera Pharma - Investing.com

Jul 30, 2024
pulisher
Jul 30, 2024

NeuroBo Signs Exclusive License Agreement With MTHERA For NB-01 - Contract Pharma

Jul 30, 2024
pulisher
Jul 30, 2024

NeuroBo Pharmaceuticals Strikes Licensing Deal for NB-01 - TipRanks

Jul 30, 2024
pulisher
Jul 17, 2024

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire Inc.

Jul 17, 2024
pulisher
Jul 17, 2024

NeuroBo Pharmaceuticals (NASDAQ:NRBO) Shares Down 3.4% - Defense World

Jul 17, 2024
pulisher
Jul 16, 2024

BIX 2024: From graveyard to breakthrough, MASH candidates on rise - BioWorld Online

Jul 16, 2024

Finanzdaten der Neurobo Pharmaceuticals Inc-Aktie (NRBO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):